PFEPFIZER INC

NYSE pfizer.com


$ 28.81 $ -0.75 (-2.54 %)    

Thursday, 06-Jun-2024 15:59:59 EDT
QQQ $ 462.33 $ 0.78 (0.17 %)
DIA $ 389.27 $ 0.80 (0.21 %)
SPY $ 534.63 $ -0.01 (0 %)
TLT $ 91.67 $ 0.05 (0.05 %)
GLD $ 214.44 $ 0.15 (0.07 %)
$ 28.8
$ 29.39
$ 0.00 x 0
$ 0.00 x 0
$ 28.79 - $ 29.54
$ 24.83 - $ 38.23
35,360,443
na
164.07B
$ 0.58
nm
TBD
na
na ($ 0.06)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-08-2023 10-01-2023 10-Q
4 08-09-2023 07-02-2023 10-Q
5 05-10-2023 04-02-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-09-2022 10-02-2022 10-Q
8 08-10-2022 07-03-2022 10-Q
9 05-11-2022 04-03-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-12-2021 10-03-2021 10-Q
12 08-12-2021 07-04-2021 10-Q
13 05-13-2021 04-04-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-27-2020 10-Q
16 08-06-2020 06-28-2020 10-Q
17 05-07-2020 03-29-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-07-2019 09-29-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 07-01-2018 10-Q
25 05-10-2018 04-01-2018 10-Q
26 02-22-2018 12-31-2017 10-K
27 11-09-2017 10-01-2017 10-Q
28 08-10-2017 07-02-2017 10-Q
29 05-11-2017 04-02-2017 10-Q
30 02-23-2017 12-31-2016 10-K
31 11-10-2016 10-02-2016 10-Q
32 08-11-2016 07-03-2016 10-Q
33 05-12-2016 04-03-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-05-2015 09-27-2015 10-Q
36 08-06-2015 06-28-2015 10-Q
37 05-07-2015 03-29-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-06-2014 09-28-2014 10-Q
40 08-07-2014 06-29-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

- Bloomberg

Core News & Articles

Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by ...

Core News & Articles

https://globalnews.ca/news/10547712/bird-flu-death-mexico-h5n2/#:~:text=It%20started%20on%20April%2017,to%20complications%20of%...

Core News & Articles

- Bloomberg

Core News & Articles

- Reuters

 whats-going-on-with-novavax-stock

Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look...

 alphabet-ventas-asml-and-a-pharmaceutical-giant-on-cnbcs-final-trades

Alphabet recently declared a $2 billion investment plan to establish its inaugural data center and Google Cloud region in Malay...

Core News & Articles

- Reuters

 promising-trial-results-show-new-standards-in-cancer-treatment-and-diagnostics-are-on-the-horizon

On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a...

Core News & Articles

https://www.youtube.com/watch?v=qCsEbq9SpsM 

Core News & Articles

- Reuters - Reuters 

Core News & Articles

The four-year analysis showed superior progression-free survival (PFS) and improved tolerability for patients compared to a cur...

 pfizer-highlights-unprecedented-5-year-data-from-cancer-drug-in-rare-form-of-advanced-lung-cancer

Pfizer's Phase 3 CROWN trial results show Lorbrena significantly outperforms Xalkori in treating ALK-positive advanced NSCLC.

 how-to-earn-500-a-month-from-pfizer-stock

New York-based Pfizer currently has a dividend yield of 5.96% — a quarterly dividend of 42 cents a share ($1.68 a year).

 pfizers-lorbrena-crown-study-shows-majority-of-patients-with-alk-positive-advanced-lung-cancer-living-beyond-5-years-without-disease-progression

An unprecedented 60% of patients remain alive without disease progression after five yearsUpdated results show continued 81% re...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION